大麻和大麻素药物研发：评估植物源与单分子方法。
Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches.
机构信息
a Department of Psychiatry , University of Pennsylvania Perelman School of Medicine , Philadelphia , PA , USA.
b National Center for Natural Product Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy , University of Mississippi , University , MS , USA.
出版信息
Int Rev Psychiatry. 2018 Jun;30(3):277-284. doi: 10.1080/09540261.2018.1474730.
Abstract
Accumulating evidence suggests that the endocannabinoid system is a promising target for the treatment of a variety of health conditions. Two paths of cannabinoid drug development have emerged. One approach is focused on developing medications that are directly derived from the cannabis plant. The other utilizes a single molecule approach whereby individual phytocannabinoids or novel cannabinoids with therapeutic potential are identified and synthesized for pharmaceutical development. This commentary discusses the unique challenges and merits of botanical vs single molecule cannabinoid drug development strategies, highlights how both can be impacted by legalization of cannabis via legislative processes, and also addresses regulatory and public health considerations that are important to consider as cannabinoid medicine advances as a discipline.
摘要
越来越多的证据表明，内源性大麻素系统是治疗多种健康状况的有前途的靶点。大麻素药物开发有两种途径。一种方法是专注于开发直接从大麻植物中提取的药物。另一种方法是采用单分子方法，即鉴定和合成具有治疗潜力的单一植物大麻素或新型大麻素，以进行药物开发。本评论讨论了植物大麻素与单分子大麻素药物开发策略的独特挑战和优点，强调了立法过程中通过大麻合法化如何影响这两种策略，还讨论了在大麻素药物作为一门学科发展过程中需要考虑的监管和公共卫生方面的考虑因素。
相似文献
1
Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches.大麻和大麻素药物研发：评估植物源与单分子方法。
Int Rev Psychiatry. 2018 Jun;30(3):277-284. doi: 10.1080/09540261.2018.1474730.
2
Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.在吸食植物大麻与合成大麻素药物的个体中观察到的不同生理和行为线索。
Clin Toxicol (Phila). 2016;54(1):14-9. doi: 10.3109/15563650.2015.1101769.
3
The legalization of cannabinoid products and standardizing cannabis-drug development in the United States: a brief report
.美国大麻素产品合法化和大麻药物开发标准化：简要报告。
Dialogues Clin Neurosci. 2020 Sep;22(3):289-293. doi: 10.31887/DCNS.2020.22.3/jmarcu.
4
Cannabinoids: for better and for worse
.大麻素：有好有坏。
Dialogues Clin Neurosci. 2020 Sep;22(3):201-204. doi: 10.31887/DCNS.2020.22.3/fthibaut.
5
Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.大麻素在癫痫发作、癫痫、癫痫发生及癫痫相关神经保护动物模型中的治疗作用。
Epilepsy Behav. 2017 May;70(Pt B):319-327. doi: 10.1016/j.yebeh.2016.11.006. Epub 2017 Feb 9.
6
Therapeutic potential of cannabinoids in combination cancer therapy.大麻素联合癌症疗法的治疗潜力。
Adv Biol Regul. 2021 Jan;79:100774. doi: 10.1016/j.jbior.2020.100774. Epub 2021 Jan 6.
7
A regulatory take on cannabis and cannabinoids for medicinal use in the European Union.关于在欧盟将大麻和大麻素用于药用的监管措施。
Arh Hig Rada Toksikol. 2020 Mar 1;71(1):12-18. doi: 10.2478/aiht-2020-71-3302.
8
Should Oncologists Recommend Cannabis?肿瘤医生是否应该推荐大麻？
Curr Treat Options Oncol. 2019 Jun 3;20(7):59. doi: 10.1007/s11864-019-0659-9.
9
The Surprising Reach of FDA Regulation of Cannabis, Even After Descheduling.即使在大麻被重新分类后，美国食品药品监督管理局（FDA）对其监管的影响仍令人惊讶。
Am Univ Law Rev. 2019;68(3):823-925.
10
The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview.大麻素作为镇痛剂的未来：药理学、药代动力学及药效学概述
Am J Ther. 2007 Sep-Oct;14(5):475-83. doi: 10.1097/MJT.0b013e3180a5e581.
引用本文的文献
1
CANDI: a web server for predicting molecular targets and pathways of cannabis-based therapeutics.CANDI：一个用于预测大麻素类疗法分子靶点和途径的网络服务器。
J Cannabis Res. 2025 Feb 27;7(1):13. doi: 10.1186/s42238-025-00268-w.
2
Research and Clinical Practice Involving the Use of Products, with Emphasis on Cannabidiol: A Narrative Review.涉及产品使用的研究与临床实践，重点是大麻二酚：一项叙述性综述。
Pharmaceuticals (Basel). 2024 Dec 6;17(12):1644. doi: 10.3390/ph17121644.
3
CANDI: A Web Server for Predicting Molecular Targets and Pathways of Cannabis-Based Therapeutics.CANDI：一个用于预测大麻基疗法分子靶点和通路的网络服务器。
Res Sq. 2024 Aug 9:rs.3.rs-4744915. doi: 10.21203/rs.3.rs-4744915/v1.
4
Pharmacohistory of Cannabis Use-A New Possibility in Future Drug Development for Gastrointestinal Diseases.大麻使用的药物史——未来胃肠道疾病药物开发的新可能性。
Int J Mol Sci. 2023 Sep 28;24(19):14677. doi: 10.3390/ijms241914677.
5
A Randomized, Double-Blind, Placebo-Controlled Decentralized Trial to Assess Sleep, Health Outcomes, and Overall Well-Being in Healthy Adults Reporting Disturbed Sleep, Taking a Melatonin-Free Supplement.一项随机、双盲、安慰剂对照的去中心化试验，旨在评估报告睡眠障碍、服用无褪黑素补充剂的健康成年人的睡眠、健康结果和整体幸福感。
Nutrients. 2023 Aug 30;15(17):3788. doi: 10.3390/nu15173788.
6
Decoding the Postulated Entourage Effect of Medicinal : What It Is and What It Isn't.解读药用植物假定的整体效应：其内涵与非内涵
Biomedicines. 2023 Aug 21;11(8):2323. doi: 10.3390/biomedicines11082323.
7
: a multifaceted plant with endless potentials.一种具有无限潜力的多面植物。
Front Pharmacol. 2023 Jun 15;14:1200269. doi: 10.3389/fphar.2023.1200269. eCollection 2023.
8
Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies.超越疼痛缓解：大麻二酚在医学治疗中的潜力综述
Pharmaceuticals (Basel). 2023 Jan 20;16(2):155. doi: 10.3390/ph16020155.
9
Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study.医用大麻用于慢性血液透析患者的疼痛管理：随机、双盲、交叉、可行性研究。
Clin Kidney J. 2022 Dec 23;16(4):701-710. doi: 10.1093/ckj/sfac275. eCollection 2023 Apr.
10
Clinical Research Evidence Supporting Administration and Dosing Recommendations of Medicinal Cannabis as Analgesic in Cancer Patients.支持药用大麻用于癌症患者镇痛的给药及剂量建议的临床研究证据。
J Clin Med. 2022 Dec 30;12(1):307. doi: 10.3390/jcm12010307.
本文引用的文献
1
Labeling Accuracy of Cannabidiol Extracts Sold Online.在线销售的大麻二酚提取物的标签准确性。
JAMA. 2017 Nov 7;318(17):1708-1709. doi: 10.1001/jama.2017.11909.
2
Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder: A Systematic Review.植物源性大麻治疗创伤后应激障碍的利弊：系统评价。
Ann Intern Med. 2017 Sep 5;167(5):332-340. doi: 10.7326/M17-0477. Epub 2017 Aug 15.
3
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.大麻二酚治疗耐药性癫痫患者：一项开放标签的干预性试验。
Lancet Neurol. 2016 Mar;15(3):270-8. doi: 10.1016/S1474-4422(15)00379-8. Epub 2015 Dec 24.
4
Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products.食用医用大麻产品中大麻素剂量与标签准确性
JAMA. 2015;313(24):2491-3. doi: 10.1001/jama.2015.6613.
5
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.医用大麻素：系统评价和荟萃分析。
JAMA. 2015;313(24):2456-73. doi: 10.1001/jama.2015.6358.
6
The entourage effect of the phytocannabinoids.植物大麻素的随行效应。
Ann Neurol. 2015 Jun;77(6):1083. doi: 10.1002/ana.24402. Epub 2015 Apr 9.
7
The medicinal use of cannabis and cannabinoids--an international cross-sectional survey on administration forms.大麻和大麻素的药用用途--管理形式的国际横断面调查。
J Psychoactive Drugs. 2013 Jul-Aug;45(3):199-210. doi: 10.1080/02791072.2013.805976.
8
Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?与 Δ(9)-THC 相比，K2 合成大麻素具有独特的药理学和代谢：毒性更大的潜在机制？
Life Sci. 2014 Feb 27;97(1):45-54. doi: 10.1016/j.lfs.2013.09.017. Epub 2013 Sep 29.
9
Beyond THC: The New Generation of Cannabinoid Designer Drugs.超越四氢大麻酚：新一代大麻素类设计药物。
Front Behav Neurosci. 2011 Sep 21;5:60. doi: 10.3389/fnbeh.2011.00060. eCollection 2011.
10
A survey study to characterize use of Spice products (synthetic cannabinoids).一项调查研究，旨在描述 Spice 产品（合成大麻素）的使用情况。
Drug Alcohol Depend. 2012 Jan 1;120(1-3):238-41. doi: 10.1016/j.drugalcdep.2011.07.011. Epub 2011 Aug 10.
Zotero 插件